Innovative Targeting Strategies in Breast Cancer Therapy.

Format:

Book

Author/Creator:

Singh, Pankaj Kumar.

Contributor:

Chourasia, Manish K.

Dua, Kamal.

Singh, Sachin Kumar.

Guru, Santosh Kumar.

Language:

English

Physical Description:

1 online resource (433 pages)

Edition:

1st ed.

Place of Publication:

Chantilly : Elsevier Science & Technology, 2025.

Summary:

Innovative Targeting Strategies in Breast Cancer Therapy is a comprehensive reference addressing the challenge of non-specific drug distribution in the body, along with severe toxicity and adverse effects, by offering insights into targeted breast cancer treatment.

Contents:

Front Cover

Front Matter

Copyright

Contents

Contributors

Chapter 1 Chemotherapeutic drugs and their side effects, BC biomarkers, detection, levels of targeting, and EPR

1.1 Introduction

1.2 Breast cancer diagnosis

1.2.1 Imaging modalities

1.2.2 BC biomarkers

1.2.3 Advanced BC detection systems

1.3 Chemotherapeutic interventions in BC

1.3.1 Neoadjuvant chemotherapy

1.3.2 Adjuvant chemotherapy

1.3.3 Chemotherapy for the metastatic breast cancer

1.3.4 Combination chemotherapy for metastasis breast cancer

1.4 Chemotherapy-related side effects

1.4.1 Nephrotoxicity

1.4.2 Alopecia

1.4.3 Cardiotoxicity

1.4.4 Peripheral neuropathy

1.4.5 Cognitive impairment

1.4.6 Lymphedema

1.4.7 Febrile neutropenia

1.4.8 Vitamin D deficiency

1.5 Novel approaches for breast cancer-targeted therapy

1.5.1 Cancer vaccines

1.5.2 Immunotherapy

1.5.3 CRISPR technology

1.5.4 Other novel approaches for targeted therapy of breast cancer

1.6 Levels of drug targeting

1.6.1 Organ-level targeting

1.6.2 Cellular targeting

1.6.3 Organelle-level targeting

1.6.4 Molecular-level targeting

1.6.5 Passive targeting

1.6.6 Inverse targeting

1.6.7 Active targeting

List of abbreviations

References

Chapter 2 Receptor-ligand-based targeting approaches in breast cancer

2.1 Introduction

2.2 Receptor targets in breast cancer treatment

2.2.1 Estrogen receptor

2.2.2 Progesterone receptors

2.2.3 Androgen receptors

2.2.4 Glucocorticoid receptor

2.2.5 Peroxisome proliferator-activated receptors

2.2.6 Retinoic acid

2.2.7 Vitamin D receptor

2.2.8 Transferrin

2.2.9 Vitamin-based targeting

2.2.10 Epidermal growth factor receptor-based active targeting

2.2.11 Hyaluronic acid

2.2.12 Antibody-based targeting approaches

2.2.13 Aptamers.

2.2.14 Folic acid

2.3 Future perspective

2.4 Conclusion

Chapter 3 Stimuli-based targeting to breast cancer

3.1 Introduction

3.2 Current treatment strategy in breast cancer

3.3 Significance of targeted nano drug delivery in breast cancer

3.4 Stimulus-based nanocarriers for breast cancer targeting

3.5 Intrinsic/endogenous stimulus-responsive nanocarriers for breast cancer targeting

3.5.1 pH-responsive nanocarriers for breast cancer targeting

3.5.2 Redox-responsive nanocarriers for breast cancer targeting

3.5.3 Enzyme-responsive nanocarriers for breast cancer targeting

3.5.4 Hypoxia-responsive nanocarriers for breast cancer targeting

3.6 Exogenous-stimulus-responsive nanocarriers for breast cancer targeting

3.6.1 Ultrasound-responsive nanocarriers for breast cancer targeting

3.6.2 Light-responsive nanocarriers for breast cancer targeting

3.6.3 Magnetic-responsive nanocarriers for breast cancer targeting

3.6.4 Thermo-responsive nanocarriers for breast cancer targeting

3.7 Major challenges and future outlook

3.8 Conclusion

Chapter 4 Advanced strategies for targeting severe triple-negative breast cancer

4.1 Introduction

4.2 Molecular characteristics of TNBC

4.2.1 Molecular subtypes and heterogeneity of TNBC

4.2.2 Key genetic and molecular alterations involved

4.3 Current treatment approaches

4.3.1 Standard treatment modalities: An overview

4.3.2 Targeted therapies and their limitations in TNBC

4.4 Advanced strategies for targeting TNBC

4.4.1 Immunotherapy approaches

4.4.2 Novel targeted therapies

4.4.3 Combination strategies

4.5 Clinical trials and future directions

4.5.1 Clinical trials investigating new therapies

4.5.2 Potential future avenues and emerging strategies.

4.6 Challenges and considerations

4.6.1 Challenges in drug development and clinical trial design

4.6.2 Considerations for patient selection and biomarker development

4.7 Conclusion and future perspective

Chapter 5 Targeted therapy for BRCA gene mutations breast cancer

5.1 Introduction

5.2 Soldiers to fight against BRCA-mutated BC

5.2.1 Synthetic inhibitors

5.2.2 Biologicals

5.3 A few challenges to surmount with the approved therapy

5.3.1 Reverse mutation

5.3.2 Hypomorphic BRCA activity

5.3.3 The DNA damage response rewiring

5.3.4 Increased expression of the efflux transporters

5.4 More avenues to be explored

5.5 Conclusion

Chapter 6 Androgen receptor targeted therapy for breast cancer

6.1 Introduction

6.2 Stages of breast cancer

6.2.1 According to numbering stage system

6.2.2 According to the tumor-node-metastasis stages of breast cancer

6.3 Pathophysiology of breast cancer

6.3.1 Different signaling pathways in the pathogenesis of breast cancer are described below

6.4 Androgen receptor targeted therapies

6.5 Selective androgen receptor modulators

6.6 Androgen deprivation therapy

6.7 Clinical applications and efficacy

6.7.1 Androgen receptor as a biomarker

6.8 National clinical trial supported clinical studies research result data

6.9 Limitations

6.10 Conclusion

Chapter 7 Monoclonal antibody based breast cancer targeting

7.1 Introduction

7.2 Understanding monoclonal antibodies

7.2.1 Foundations of monoclonal antibodies

7.2.2 Mechanisms of action of monoclonal antibodies in breast cancer

7.3 Breast cancer landscape

7.3.1 Molecular heterogeneity in breast cancer

7.3.2 Targeted approaches for breast cancer

7.3.3 Case studies of breast cancer.

7.4 Monoclonal antibodies in breast cancer therapy

7.5 Customizing treatment strategies for breast cancer

7.6 Technological integration in breast cancer management

7.6.1 Integration of monoclonal antibody technology

7.6.2 Immunotherapy innovations for breast cancer

7.6.3 Biomarker-Driven Strategies for Breast Cancer

7.7 Challenges and future directions in breast cancer

7.8 Conclusion

Chapter 8 Breast cancer stem cell targeting

8.1 Introduction

8.2 Breast cancer stem cells

8.2.1 Specifications

8.3 Importance of targeting BCSCs in breast cancer

8.3.1 Challenges posed by BCSCs in conventional cancer therapies

8.3.2 Significance of BCSC targeting in improving treatment outcomes and reducing relapse rates

8.4 Molecular signaling pathways and BCSCs in breast cancer

8.4.1 Key molecular pathways regulating BCSC

8.4.2 Specific signaling pathways implicated in breast cancer stemness

8.5 Therapeutic approaches targeting breast cancer stem cells

8.5.1 Chemotherapeutic agents targeting BCSCs and mechanisms of action

8.5.2 Personalized therapy

8.6 Preclinical and clinical studies

8.6.1 Clinical trials investigating the efficacy and safety of BCSC-targeted therapies in breast cancer patients

8.7 Novel technologies and approaches

8.7.1 Emerging technologies for studying BCSC biology and heterogeneity

8.7.2 Innovative drug delivery systems and nanomedicine approaches for enhancing BCSC-targeted therapy efficacy

8.7.3 Personalized medicine strategies integrating BCSC biomarkers and patient specific characteristics for optimized treatment outcomes

8.8 Future directions and challenges

8.8.1 Finding novel BCSC biomarkers

8.8.2 BCSC heterogeneity characterization

8.8.3 Targeting BCSC-specific signaling pathways

8.8.4 Progression of utilitarian drug delivery systems.

8.8.5 Inclusion of immuno-oncological and BCSC-targeted therapies

8.8.6 Translation into clinic and validation of candidate biomarker

8.9 Unmet needs and challenges in effectively targeting BCSCs in breast cancer

8.9.1 Diversity of BCSCs

8.9.2 Specific biomarkers absence

8.9.3 Resistance mechanisms

8.9.4 Influence of the tumor microenvironment

8.9.5 Drug delivery problems to BCSC niches

8.9.6 Absence of preclinical models

8.9.7 Challenges in clinical translation

8.10 Approaches to combat resistance to treatment

8.10.1 Targeted treatment

8.10.2 Y-combination

8.10.3 Studying circulating tumor cells

8.10.4 Tumor microenvironment workarounds

8.10.5 Adaptive treatment

8.11 Conclusion

Chapter 9 The role of hormone receptors in breast cancer: New opportunities for treatment and prevention

9.1 Introduction

9.2 Hormone receptors

9.2.1 Estrogen receptors

9.2.2 Progesterone receptors

9.2.3 Androgen receptors

9.2.4 Glucocorticoid receptors

9.3 Molecular mechanisms causing loss of hormone receptor expression in breast cancer cells

9.4 Genetic mechanisms

9.5 Epigenetic mechanisms

9.6 Growth factor signaling

9.7 Posttranscriptional regulation of er&amp

#x03B1

expression

9.8 Posttranslational regulation of ER&amp

9.9 The role of hypoxia

9.10 Intratumor heterogeneity

9.11 Clinical presentation and management

9.12 Therapeutic implications

9.13 First-line treatment

9.14 Second-line treatment

9.15 Conclusions

Chapter 10 HER2-positive (HER2+) &amp

HER2-negative (HER2−) targeted therapies

10.1 Introduction

10.2 Various therapies involved in the management of breast cancer

10.3 Characteristics of hormone-dependent breast cancer-Human epidermal growth factor receptor 2.

10.3.1 Human epidermal growth factor receptor 2.

Notes:

Description based on publisher supplied metadata and other sources.

ISBN:

0-443-33350-5

9780443333507

OCLC:

1546815974